Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 8 14 SULFITE FREE IN DEXTROSE 14 IN PLASTIC CONTAINER versus PROCALAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX 8 14 SULFITE FREE IN DEXTROSE 14 IN PLASTIC CONTAINER versus PROCALAMINE.
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER vs PROCALAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
Intravenous infusion. Dose individualized based on metabolic requirements, energy expenditure, and clinical status. Typical adult dose: 500 mL to 1000 mL per day, providing 8% amino acids and 14% dextrose, infused at a rate not exceeding 0.1 g/kg/hr of amino acids and 0.5 g/kg/hr of dextrose.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
None Documented
None Documented
Not applicable as individual components (amino acids, dextrose, electrolytes) are not eliminated via first-order kinetics; amino acids have a plasma half-life of minutes to hours depending on metabolic demand and renal function.
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Renal excretion of urea and other nitrogenous waste products; no biliary or fecal elimination of nutrients.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution